Sunlenca package insert
WebSUNLENCA tablets are packaged in a blister pack containing: 5 tablets of SUNLENCA, each containing 300 mg of lenacapavir, in a clear blister film sealed to a foil lidding material. … WebLenacapavir (Sunlenca ®) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and …
Sunlenca package insert
Did you know?
WebDec 21, 2024 · 2.2 Missed Dose. During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, using either Option 1 or Option 2 [see Dosage and Administration (2.1)].. 2.3 Preparation and Administration of … WebDec 21, 2024 · 7.2 Effect of SUNLENCA on Other Drugs Lenacapavir is a moderate inhibitor of CYP3A. Due to the long half-life of lenacapavir following subcutaneous administration, …
WebDec 21, 2024 · NDC 61958-3001-1 - Sunlenca® (lenacapavir) tablets - 300 mg per tablet - 1 pouch containing 4 tablets - Each tablet contains: 300 mg of lenacapavir - (present as 306.8 mg lenacapavir sodium). SUNLENCA tablets: Each tablet contains 300 mg of lenacapavir (present as 306.8 mg of lenacapavir sodium). The tablets are beige, capsule-shaped, film-coated, and debossed with ‘GSI’ on one side of the tablet and ‘62L’ on the other side of the tablet. SUNLENCA injection: Each single-dose vial contains 463.5 mg/1.5 mL
WebBrand and Other Names: Sunlenca Classes: Capsid Inhibitors Print Dosing & Uses AdultPediatric Dosage Forms & Strengths injection, solution 463.5mg/1.5mL (309mg/mL) single-dose vial Each kit... WebSunlenca (300 mg tablet and 463.5 mg/1.5 mL injection) is a first-in-class, long-acting HIV capsid inhibitor approved in the United States, the United Kingdom, Canada and the European Union, for the treatment of HIV infection, in combination with other antiretroviral (s), in people with multi-drug resistant HIV who are heavily …
WebDec 22, 2024 · Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV – Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option – – New Drug Application Approval Based on High Rates of Sustained Virologic Suppression in the …
WebPrior Authorization is recommended for prescription benefit coverage of Sunlenca. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Sunlenca as well as the monitoring required for adverse events and long-term efficacy, approval bliss trillickWebSUNLENCA tablets are packaged in a blister pack containing: 5 tablets of SUNLENCA, each containing 300 mg of lenacapavir, in a clear blister film sealed to a foil lidding material. The blister card, which is fitted between child-resistant sealed paperboard cards, is packaged with silica gel desiccant in a sealed flexible laminated pouch. free accelerated direct3d devices downloadWebGilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 800-445-3235 Week 52 Subgroup Efficacy of Lenacapavir in Heavily Treatment-Experienced PWH 523 Onyema Ogbuagu,1* Sorana Segal-Maurer,2 Antonella Castagna,3 Edwin DeJesus,4 Anchalee Avihingsanon,5 Christine Zurawski,6 Olayemi Osiyemi,7 Theo Hodge,8 Gordon E. Crofoot,9 … bliss trip with meWebSUNLENCA is a prescription medication that is used with other human immunodeficiency virus-1 (HIV-1) medicines to treat HIV-1 infection in adults: who have received HIV-1 … bliss tried blue air freshenerWebMar 10, 2024 · Sunlenca is a brand-name medication that’s FDA approved to treat HIV in adults. It comes as an under-the-skin (subcutaneous) injection and oral tablet. It’s used in combination with other HIV medications to help keep the condition under control. However, Sunlenca isn’t meant for everyone living with HIV. freeaccessWebOct 4, 2024 · Sunlenca 300 mg film coated tablets Active Ingredient: lenacapavir sodium Company: Gilead Sciences Ltd See contact details ATC code: J05AX31 About Medicine Prescription only medicine Healthcare Professionals (SmPC) Patient Leaflet (PIL) This information is for use by healthcare professionals Last updated on emc: 04 Oct 2024 … bliss try me freeWeb* Sunlenca tablet: , in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 and 5. 1). bliss tub manufacturer